活性氧调节因子 1 与腺苷脱氨酶联合检测在鉴别 NSCLC 相关恶性胸腔积液中的临床价值。
Clinical value of combined detection of reactive oxygen species modulator 1 and adenosine deaminase in pleural effusion in the identification of NSCLC associated malignant pleural effusion.
机构信息
Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Science and Education Department, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
出版信息
J Clin Lab Anal. 2020 Mar;34(3):e23091. doi: 10.1002/jcla.23091. Epub 2019 Nov 10.
BACKGROUND
Reactive oxygen species modulator 1 (ROMO1) is recognized to be involved in cell proliferation and is elevated in serum of various cancer patients. However, ROMO1 had little research in distinguishing between malignant pleural effusions (MPEs) and benign pleural effusions (BPEs).
METHODS
Malignant pleural effusion samples from patients with non-small-cell lung cancer (NSCLC) and benign pleural effusion (BPE) samples containing tuberculous and inflammatory pleural effusions were collected. The samples were tested for ROMO1, pleural effusion adenosine deaminase (pADA), pleural effusion carbohydrate antigen (pCA125, pCA153, pCA199), pleural effusion ferritin (pFER), and pleural effusion lactate dehydrogenase (pLDH) levels, and the other relevant partial clinical data that were gathered were used to conduct statistical analysis.
RESULTS
The ROMO1, pCA125, pCA199, pCA153, pADA + ROMO1, pCA153 + ROMO1, pCA125 + ROMO1, and pCA199 + ROMO1 levels in MPE were appreciably higher in comparison with BPE group (all P = .000). The concentration of pADA in MPE was markedly lower than BPE (P = .000). When the cutoff = 0.38, the sensitivity of combined detection of ROMO1 + pADA is 98.67% and the specificity is 70.73%, respectively, and the AUC (0.941) is the highest among other parameters.
CONCLUSION
The combined detection of ROMO1 + ADA in pleural effusion is an effective biomarker for identifying MPE caused by NSCLC.
背景
活性氧物种调节剂 1（ROMO1）被认为参与细胞增殖，并且在各种癌症患者的血清中升高。然而，ROMO1 在区分恶性胸腔积液（MPE）和良性胸腔积液（BPE）方面的研究较少。
方法
收集非小细胞肺癌（NSCLC）患者的恶性胸腔积液样本和包含结核性和炎症性胸腔积液的良性胸腔积液（BPE）样本。测试样本的 ROMO1、胸腔积液腺苷脱氨酶（pADA）、胸腔积液糖抗原（pCA125、pCA153、pCA199）、胸腔积液铁蛋白（pFER）和胸腔积液乳酸脱氢酶（pLDH）水平，以及收集的其他相关部分临床数据进行统计分析。
结果
与 BPE 组相比，MPE 中的 ROMO1、pCA125、pCA199、pCA153、pADA+ROMO1、pCA153+ROMO1、pCA125+ROMO1 和 pCA199+ROMO1 水平明显更高（均 P=0.000）。MPE 中的 pADA 浓度明显低于 BPE（P=0.000）。当截断值=0.38 时，ROMO1+pADA 联合检测的灵敏度为 98.67%，特异性为 70.73%，AUC（0.941）是其他参数中最高的。
结论
胸腔积液中 ROMO1+ADA 的联合检测是识别 NSCLC 引起的 MPE 的有效生物标志物。
Zotero 插件